Altimmune (NASDAQ:ALT) Issues Quarterly Earnings Results

Altimmune (NASDAQ:ALT) issued its quarterly earnings results on Tuesday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03, Zacks reports. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the firm earned ($0.39) earnings per share.

Altimmune Stock Performance

ALT opened at $8.46 on Friday. Altimmune has a 52-week low of $2.34 and a 52-week high of $14.84. The firm has a market cap of $601.32 million, a P/E ratio of -5.45 and a beta of 0.09. The business’s fifty day moving average is $6.99 and its 200-day moving average is $6.90.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALT. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday. They set a “buy” rating and a $26.00 price objective for the company. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Insider Buying and Selling

In other Altimmune news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. The trade was a 27.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is currently owned by company insiders.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.